ClinicalTrials.gg
CompletedNCT01429792Updated Oct 23, 2018Results posted

A Study Evaluating Slow Response/Non-Rapid Response in Patients With Chronic Hepatitis C, Genotype 1, 2, 3 & 4 Treated With Pegasys (Peginterferon Alfa-2a) and Copegus (Ribavirin)

A Phase 4 interventional study of peginterferon alfa-2a [Pegasys] and ribavirin [Copegus] in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 26 sites in Israel. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-10-23.

Sponsored by Hoffmann-La Roche · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 2 years 11 months after the study started (first participant enrolled Sep 2008, registered Sep 2011).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
1,013
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic — none open to participants now, none under way, none of them phase 3. peginterferon alfa-2a · Hepatitis C, Chronic.

Enrollment
5th of 83
1,013 · median 129
Started
2008
with 3 others
Phase 4
48 of 83
none open now
Registered
62nd of 83
by date
Lead sponsor
35 of 83
Hoffmann-La Roche

Among the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic, this one is the 5th largest by enrollment, is one of 4 that started in 2008, is one of 48 in phase 4, and was the 62nd registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

None of the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic is open now. The open studies under Hepatitis C, Chronic, anywhere →

About peginterferon alfa-2a

peginterferon alfa-2a: first FDA approval 2002 (PEGASYS), first EMA approval 2002. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 83 studies testing peginterferon alfa-2a in Hepatitis C, Chronic as a file.
02

Study summary

This multi-center study will evaluate the viral response in patients with chronic hepatitis C, genotype 1, 2, 3 \& 4 on standard anti-viral treatment with Pegasys (peginterferon alfa-2a) and Copegus (ribavirin). Patients will receive weekly subcutaneous Pegasys plus daily oral Copegus for 24 weeks (genotype 2 \& 3) or 48 weeks (genotype 1 \& 4). Patients identified as slow responders/non-rapid virological responders will be eligible for an additional 24 weeks of treatment.

03

Conditions studied

  • Hepatitis C, Chronic

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult patients, >/= 18 years of age
  • Serologic evidence of chronic , genotype 1, 2, 3 or 4 by anti-HCV antibody test
  • Documented pre-treatment HCV RNA quantitative result
  • Compensated liver disease ( Grade A)
  • Patient receiving standard combination treatment of Pegasys (peginterferon alfa-2a and Copegus (ribavirin)

Exclusion criteria

Exclusion Criteria:

  • Decompensated liver disease ( Class B or C cirrhosis)
  • Co-infection with active hepatitis A and/or
  • History or evidence of a medical condition associated with liver disease other than
  • Signs and symptoms of hepatocellular carcinoma
  • History of poorly controlled thyroid disease, elevated TSH or any clinical manifestations of thyroid disease
  • Therapy with antineoplastic treatment \</= 6 months prior to study day
  • Diabetes mellitus in subjects receiving an insulin therapy
  • Evidence of severe retinopathy
  • Pregnant or breast-feeding women, and male partners of women who are pregnant
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Child-Pugh class

A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
1,013 participants (actual)

Study arms

  • Experimental
    Single Arm

    Drug: peginterferon alfa-2a [Pegasys] · Drug: ribavirin [Copegus]

Interventions

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Partial Early Virological Response (pEVR) to Study Treatment

    The rate of participants with pEVR to study treatment was defined as ≥ 2 log reduction in HCV-RNA level from baseline value to Week 12 of study treatment but with detectable HCV-RNA at Week 12.

    Time frame: Week 12

  2. Percentage of Participants With Complete Early Virologic Response (cEVR) to Study Treatment

    The rate of participants with a cEVR to study treatment was defined as negative HCV-RNA level at Week 12 of study treatment

    Time frame: Week 12

  3. Percentage of Participants With Undetectable HCV-RNA at End of Treatment Response (ETR) at Week 24

    The rate of participants with undetectable HCV-RNA at ETR at Week 24 was defined as at least a 2-log decrement in HCV-RNA from the start of treatment, but with detectable HCV-RNA at Week 12 of study treatment and undetectable HCV-RNA at Week 24 of study treatment

    Time frame: Week 24

  4. Percentage of Participants With Rapid Virologic Response (RVR) at Week 4

    The rate of participants with RVR was defined as negative HCV-RNA level at Week 4 of study treatment.

    Time frame: Week 4

  5. Percentage of Participants Without a RVR (Non-RVR) at Week 4 of Standard Treatment

    The rate of participants without a RVR (non-RVR) was defined as detectible HCV-RNA level at Week 4 of standard treatment.

    Time frame: Week 4

  6. Percentage of Participants With Non-RVR and Undetectable HCV-RNA at Week 24

    The rate of participants with non-RVR and undetectable HCV-RNA at Week 24 was defined as detectable HCV-RNA level at Week 4 of study treatment and undetectable HCV-RNA at Week 24 of study.

    Time frame: Week 24

Secondary outcomes

  1. Percentage of Participants With pEVR to Study Treatment at Week 12

    The rate of participants with pEVR to study treatment was defined as ≥ 2 log reduction in HCV-RNA level from baseline value to Week 12 of study treatment but with detectable HCV-RNA at Week 12.

    Time frame: Week 12

  2. Percentge of Participants With a cEVR to Study Treatmen at Week 12 of Study Treatment

    The rate of participants with a cEVR to study treatment was defined as negative HCV-RNA level at Week 12 of study treatment.

    Time frame: Week 12

  3. Percentage of Participants With Undetectable HCV-RNA at Week 24, But With Detectable HCV-RNA atWeek 12 and Undetectable HCV-RNA at Week 24

    The rate of participants with undetectable HCV-RNA at ETR at Week 24 was defined as at least a 2-log decrement in HCV-RNA from the start of treatment, but with detectable HCV-RNA at Week 12 of study treatment and undetectable HCV-RNA at Week 24 of study treatment.

    Time frame: Week 24

07

Results

Posted Oct 23, 2018

Participant flow

Male and female participants, 18 years of age and above with serologically proven genotype 1, 2, 3 or 4 CHC and treated with the standard combination treatment of peginterferon alfa-2a (Pegasys) and ribavirin (Copegus).

Participant flow — Overall Study
MilestonePegylated Interferon Alfa 2a (Peginterferon)
Started1013
Genotype 1687
Genotype 2 & 3305
Genotype 45
Completed607
Not completed406
Withdrew: Other reasons67
Withdrew: Unknown disposition94
Withdrew: Negative hcv-rna at week 41
Withdrew: Negative hcv-rna at week 124
Withdrew: Decrease of less than 2-log in hcv rna32
Withdrew: Positive hcv-rna at week 2450
Withdrew: Withdrawal by subject70
Withdrew: Lost to follow-up88

Outcome measures

PrimaryPercentage of Participants With Partial Early Virological Response (pEVR) to Study Treatment

The rate of participants with pEVR to study treatment was defined as ≥ 2 log reduction in HCV-RNA level from baseline value to Week 12 of study treatment but with detectable HCV-RNA at Week 12.

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Partial Early Virological Response (pEVR) to Study Treatment
Percentage of participantsPegylated Interferon Alfa 2a (Peginterferon)
Percentage of Participants With Partial Early Virological Response (pEVR) to Study Treatment15.7 (12.6 to 18.1)
PrimaryPercentage of Participants With Complete Early Virologic Response (cEVR) to Study Treatment

The rate of participants with a cEVR to study treatment was defined as negative HCV-RNA level at Week 12 of study treatment

Time frame:
Week 12
Reported as:
Number · Percentage of participants
Percentage of Participants With Complete Early Virologic Response (cEVR) to Study Treatment
Percentage of participantsPegylated Interferon Alfa 2a (Peginterferon)
Percentage of Participants With Complete Early Virologic Response (cEVR) to Study Treatment50.8 (46.8 to 54.4)
PrimaryPercentage of Participants With Undetectable HCV-RNA at End of Treatment Response (ETR) at Week 24

The rate of participants with undetectable HCV-RNA at ETR at Week 24 was defined as at least a 2-log decrement in HCV-RNA from the start of treatment, but with detectable HCV-RNA at Week 12 of study treatment and undetectable HCV-RNA at Week 24 of study treatment

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Undetectable HCV-RNA at End of Treatment Response (ETR) at Week 24
Percentage of participantsPegylated Interferon Alfa 2a (Peginterferon)
Percentage of Participants With Undetectable HCV-RNA at End of Treatment Response (ETR) at Week 2415.6 (12.9 to 19.2)
PrimaryPercentage of Participants With Rapid Virologic Response (RVR) at Week 4

The rate of participants with RVR was defined as negative HCV-RNA level at Week 4 of study treatment.

Time frame:
Week 4
Reported as:
Number · Percentage of participants
Percentage of Participants With Rapid Virologic Response (RVR) at Week 4
Percentage of participantsPegylated Interferon Alfa 2a (Peginterferon)
Percentage of Participants With Rapid Virologic Response (RVR) at Week 448.03 (42.3 to 53.6)
PrimaryPercentage of Participants Without a RVR (Non-RVR) at Week 4 of Standard Treatment

The rate of participants without a RVR (non-RVR) was defined as detectible HCV-RNA level at Week 4 of standard treatment.

Time frame:
Week 4
Reported as:
Number · Percentage of participants
Percentage of Participants Without a RVR (Non-RVR) at Week 4 of Standard Treatment
Percentage of participantsPegylated Interferon Alfa 2a (Peginterferon)
Percentage of Participants Without a RVR (Non-RVR) at Week 4 of Standard Treatment51.97 (46.2 to 57.6)
PrimaryPercentage of Participants With Non-RVR and Undetectable HCV-RNA at Week 24

The rate of participants with non-RVR and undetectable HCV-RNA at Week 24 was defined as detectable HCV-RNA level at Week 4 of study treatment and undetectable HCV-RNA at Week 24 of study.

Time frame:
Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants With Non-RVR and Undetectable HCV-RNA at Week 24
Percentage of participantsPegylated Interferon Alfa 2a (Peginterferon)
Percentage of Participants With Non-RVR and Undetectable HCV-RNA at Week 246.9 (4.3 to 10.3)
SecondaryPercentage of Participants With pEVR to Study Treatment at Week 12

The rate of participants with pEVR to study treatment was defined as ≥ 2 log reduction in HCV-RNA level from baseline value to Week 12 of study treatment but with detectable HCV-RNA at Week 12.

Time frame:
Week 12

No measurements were reported for this outcome.

SecondaryPercentge of Participants With a cEVR to Study Treatmen at Week 12 of Study Treatment

The rate of participants with a cEVR to study treatment was defined as negative HCV-RNA level at Week 12 of study treatment.

Time frame:
Week 12

No measurements were reported for this outcome.

SecondaryPercentage of Participants With Undetectable HCV-RNA at Week 24, But With Detectable HCV-RNA atWeek 12 and Undetectable HCV-RNA at Week 24

The rate of participants with undetectable HCV-RNA at ETR at Week 24 was defined as at least a 2-log decrement in HCV-RNA from the start of treatment, but with detectable HCV-RNA at Week 12 of study treatment and undetectable HCV-RNA at Week 24 of study treatment.

Time frame:
Week 24

No measurements were reported for this outcome.

Adverse events

Collected over Baseline to Week 24. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Pegylated Interferon Alfa 2a (Peginterferon)—50/1,013 (4.9%)131/1,013 (12.9%)
Most frequent serious events
Showing 10 of 48
Most frequent serious events
EventPegylated Interferon Alfa 2a (Peginterferon)
AnemiaBlood and lymphatic system disorders8/1013
PancytopeniaBlood and lymphatic system disorders3/1013
PneumoniaInfections and infestations3/1013
Urinary tract infectionInfections and infestations3/1013
Acute myocardial infarctionCardiac disorders2/1013
AstheniaGeneral disorders2/1013
AppendicitisInfections and infestations2/1013
Haemolytic anemiaBlood and lymphatic system disorders1/1013
Neutropenic feverBlood and lymphatic system disorders1/1013
Atrial fibrillationCardiac disorders1/1013
Most frequent other events
Most frequent other events
EventPegylated Interferon Alfa 2a (Peginterferon)
AnemiaBlood and lymphatic system disorders103/1013
AstheniaGeneral disorders103/1013
NeutropeniaBlood and lymphatic system disorders57/1013

Baseline characteristics

All participants who enrolled in the study

Age, Continuous
Age, Continuous(Years)Pegylated Interferon Alfa 2a (Peginterferon)
Mean43.6 ± 11.3
Sex/Gender, Customized
Sex/Gender, Customized(Participants)Pegylated Interferon Alfa 2a (Peginterferon)
Female380
Male632
Unknown1
08

Study locations

26 sites
  • Haemek Hospital; Gastroenterology
    Afula, 18101, Israel
  • Clalit City Ashdod MC; Liver Clinic
    Ashdod, 77444, Israel
  • Barzilai MC; Gastroenterology
    Ashkelon, 78278, Israel
  • Batyamon; Liver Unit
    Bat Yam, Israel
  • Soroka Medical Center; Liver Unit
    Beer Sheva, 8410101, Israel
  • Soroka Medical Center; Gastroenterology
    Beer Sheva, 84105, Israel
  • Rambam Medical Center; Gastroenterology - Liver Unit
    Haifa, 31096, Israel
  • Bnei-Zion Medical Center; Gastroenterology
    Haifa, 33394, Israel
  • Carmel Hospital; Liver Unit
    Haifa, 34362, Israel
  • Wolfson Hospital; Gastroenterology Unit
    Holon, 58100, Israel
  • Hadassah Hospital; Liver Unit
    Jerusalem, 91120, Israel
  • Clalit Strauss MC
    Jerusalem, 95146, Israel
  • Meir Medical Center; Gastroenterology
    Kfar Saba, 44281, Israel
  • Naharyia / Western Galilee MC; Gastro Unit
    Nahariya, 22100, Israel
  • Holy Family Medical Center; Gastroenterology
    Nazareth, Israel
  • Rabin Medical Center; Gastroenterology - Liver Unit
    Petach Tikva, 49100, Israel
  • Hasharon Mc; Gastroenterology
    Petach Tikva, Israel
  • Chaim Sheba Medical Center; Gastroenterology
    Ramat Gan, 52621, Israel
  • Kaplan Medical Center; Gastroenterology Unit
    Rehovot, 76100, Israel
  • Clalit Pinsker Rishon; Liver Clinic
    Rishon Lezion, 75299, Israel
  • Rebecca Sieff; Gastroenterology
    Safed, 13110, Israel
  • Sourasky / Ichilov Hospital; Gastroenterology - Liver Unit
    Tel Aviv, 6423906, Israel
  • Clalit Zamenhoff
    Tel Aviv, 64353, Israel
  • Maccabi Health Services MC
    Tel Aviv, 67891, Israel
  • Poria Hospital; Gastroenterology
    Tiberias, Israel
  • Assaf Harofeh; Gastroenterology
    Zerifin, 6093000, Israel
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2008 to primary completion in Jun 2013, 56 months.

Results were first posted in Oct 2018, 5 years 4 months after primary completion.

Of 24 phase 4 interventional studies under Hepatitis C, Chronic, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 48. This study's 56 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 5, 2011
First posted
Sep 7, 2011
StartActual
Sep 25, 2008
Primary completionActual
Jun 10, 2013
CompletionActual
Jun 10, 2013
Results first posted
Oct 23, 2018
Last update
Oct 23, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 23, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01429792
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Sep 7, 2011
Start date
Sep 25, 2008
Primary completion
Jun 10, 2013
Completion
Jun 10, 2013
Results posted
Oct 23, 2018
Last update
Oct 23, 2018

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Peginterferon alfa-2a

Start the discussion